Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenping Zhu

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Idrugs : the Investigational Drugs Journal|November 20, 2004
Monoclonal Antibodies in Cancer--Fourth International Congress. EGFR/HER1 antibodies. 3-6 September 2004, Colorado Springs, CO, USAZhenping Zhu
Idrugs : the Investigational Drugs Journal|November 20, 2004
Monoclonal Antibodies in Cancer--Fourth International Congress. HER2/neu and other antibodies. 3-6 September 2004, Colorado Springs, CO, USAZhenping Zhu
Drug Discovery Today|September 10, 2003
Aberrant tumor vasculature and angiogenesis: new opportunities for cancer therapyZhenping Zhu
Acta Pharmacologica Sinica|August 29, 2007
Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectivesZhenping Zhu
Chinese Journal of Cancer|April 30, 2011
Next generation of antibody therapy for cancerZhenping Zhu, Li Yan
Current Medicinal Chemistry|August 20, 2009
Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disordersYan Wu, Zhenping Zhu
Frontiers in Bioscience : a Journal and Virtual Library|March 17, 2005
Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspectiveKeren Paz, Zhenping Zhu
International Journal of Hematology|September 9, 2005
FLT3 antibody-based therapeutics for leukemia therapyYiwen Li, Zhenping Zhu
Expert Opinion on Therapeutic Targets|November 23, 2005
Recent advances in targeted therapy of human myelogenous leukaemiaKeren Paz, Zhenping Zhu
Acta Pharmacologica Sinica|August 10, 2010
Research and development of next generation of antibody-based therapeuticsJing Li, Zhenping Zhu
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Idrugs : the Investigational Drugs Journal|November 20, 2004
Monoclonal Antibodies in Cancer--Fourth International Congress. EGFR/HER1 antibodies. 3-6 September 2004, Colorado Springs, CO, USAZhenping Zhu
Idrugs : the Investigational Drugs Journal|November 20, 2004
Monoclonal Antibodies in Cancer--Fourth International Congress. HER2/neu and other antibodies. 3-6 September 2004, Colorado Springs, CO, USAZhenping Zhu
Drug Discovery Today|September 10, 2003
Aberrant tumor vasculature and angiogenesis: new opportunities for cancer therapyZhenping Zhu
Acta Pharmacologica Sinica|August 29, 2007
Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectivesZhenping Zhu
Chinese Journal of Cancer|April 30, 2011
Next generation of antibody therapy for cancerZhenping Zhu, Li Yan
Current Medicinal Chemistry|August 20, 2009
Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disordersYan Wu, Zhenping Zhu
Frontiers in Bioscience : a Journal and Virtual Library|March 17, 2005
Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspectiveKeren Paz, Zhenping Zhu
International Journal of Hematology|September 9, 2005
FLT3 antibody-based therapeutics for leukemia therapyYiwen Li, Zhenping Zhu
Expert Opinion on Therapeutic Targets|November 23, 2005
Recent advances in targeted therapy of human myelogenous leukaemiaKeren Paz, Zhenping Zhu
Acta Pharmacologica Sinica|August 10, 2010
Research and development of next generation of antibody-based therapeuticsJing Li, Zhenping Zhu
Pageof 13